Which company produces lorlatinib/lorlatinib?

Lorlatinib is an anticancer drug used to treat non-small cell lung cancer (NSCLC), marketed under the brand name Lorbrena in the United States, Canada and Japan, Lorviqua in the EU, and Borrena in China. Developed by Pfizer Inc., it is an oral inhibitor of anaplastic lymphoma kinase (ALK) and C-oncogene 1 (ROS1), two enzymes that play a role in the development of cancer.

Pfizer is a world-renowned pharmaceutical company with extensive R&D experience and a strong product pipeline in the field of oncology. As one of its many anti-tumor drugs, lorlatinib has received widespread attention since its launch. The drug's mechanism of action is mainly by inhibiting the activity of the ALK enzyme, thereby preventing the proliferation and growth of cancer cells. Clinical studies have shown that lorlatinib has good efficacy in most ALK-positive patients, especially when other treatments have failed, it can still provide effective therapy.

ALK belongs to a family of receptor tyrosine kinases that are involved in cell growth and the development of new blood vessels that supply cells. In patients with ALK-positive NSCLC, an abnormal form of ALK is produced, causing the cancer cells to divide and grow in an uncontrolled manner. Lorlatinib Active substance Lorlatinib is a tyrosine kinase inhibitor. It works by blocking the activity of ALK, thereby reducing the growth and spread of cancer cells.

In addition, lorlatinib has shown efficacy against brain metastases to a certain extent. Due to its ability to penetrate the blood-brain barrier, lorlatinib offers a new treatment option for these patients. In clinical trials, the safety and tolerability of lorlatinib were also relatively good, although some possible side effects, such as central nervous system-related adverse reactions, still need to be noted.